Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Merck & Co., Inc.MRK · Entity 2807 | Executive VP & President, MRL | May 05, 2026 | May 07, 2026 |
| RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008 | Director | October 01, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Merck & Co., Inc.
Report date May 05, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2029-05-05 | Direct | 19,885 |
Reported balance
After 2026-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-05 · Grant · Acquired 19,885 · Balance 19,885 F1: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $113.15 · Expires 2036-05-04 | Direct | 58,207 |
Reported balance
After 2026-05-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-05 · Grant · Acquired 58,207 · Balance 58,207 F3: The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. |
| Common StockSEC Table I · non-derivative | Direct | 94,431.05 |
Reported balance
Holding disclosure · report date 2026-05-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 94,431.05 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
F2: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029.
F3: The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029.
RECURSION PHARMACEUTICALS, INC.
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 1,476,707 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 3,378 · Balance 1,476,707 F1: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy Dean Y. Li Revocable Trust | 1,422,048 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,422,048 |
| Class A Common StockSEC Table I · non-derivative | IndirectBy Dean Y. Li 2021 Family Trust | 421,000 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 421,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 2, 2026 22:17 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 3,378 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-26-000115 · wk-form4_1790979423.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,476,707 F1 · kind: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:15 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 3,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-26-000091 · wk-form4_1783026941.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,473,329 F1 · kind: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:32 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 88,424 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-26-000083 · wk-form4_1782160325.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,469,582 F1 · kind: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 136,981 shares of Class A common stock transferred from the Dean Y. Li GRAT on May 7, 2026. Read SEC document |
| May 05, 2026 Filed May 7, 2026 16:07 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 58,207 | $0.00 Strike: $113.15 | $0.00 |
DisclosureSEC source: 0000310158-26-000133 · form4.xml · derivative · entry 3 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,207 Underlying: Common Stock · 58,207 shares Expires 2036-05-04 F3 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. Read SEC document |
| May 05, 2026 Filed May 7, 2026 16:07 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 19,885 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-26-000133 · form4.xml · derivative · entry 2 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,885 Underlying: Common Stock · 19,885 shares Expires 2029-05-05 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. Read SEC document |
| April 29, 2026 Filed May 1, 2026 21:45 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 4,722 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-26-000088 · form4.xml · derivative · entry 3 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,444 Underlying: Common Stock · 4,722 shares Expires 2028-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2026 Filed May 1, 2026 21:45 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 2,326 | $110.03 | $255,929.78 |
DisclosureSEC source: 0000310158-26-000088 · form4.xml · nonDerivative · entry 2 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,431.05 Read SEC document |
| April 29, 2026 Filed May 1, 2026 21:45 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 4,722 | $110.03 | $519,561.66 |
DisclosureSEC source: 0000310158-26-000088 · form4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,757.05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 20:56 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 3,268 | $0.00 | $0.00 |
DisclosureSEC source: 0001837016-26-000005 · wk-form4_1775163374.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,244,177 F1 · kind: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| February 10, 2026 Filed Feb 10, 2026 21:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 10,235 | $117.52 | $1,202,843.81 |
DisclosureSEC source: 0000310158-26-000050 · form4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,035.05 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.5200 to $117.5550, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 21:12 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,087 | $0.00 Strike: $56.04 | $0.00 |
DisclosureSEC source: 0000310158-26-000036 · form4.xml · derivative · entry 3 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,087 shares Expires 2028-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F3 · derivative.exercise_date: The option became exercisable in equal installments on 5/4/2019, 5/4/2020, and 5/4/2021. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 21:12 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 15,087 | $118.77 | $1,791,824.15 |
DisclosureSEC source: 0000310158-26-000036 · form4.xml · nonDerivative · entry 2 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,270.05 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.7200 to $118.8300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 21:12 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 15,087 | $56.04 | $845,475.48 |
DisclosureSEC source: 0000310158-26-000036 · form4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,357.05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 21:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 20,469 | $107.40 | $2,198,370.60 |
DisclosureSEC source: 0000310158-26-000016 · form4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,270.05 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/23. Performance shares were paid out at 94 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2025. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:47 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 2,381 | $0.00 | $0.00 |
DisclosureSEC source: 0001837016-26-000003 · wk-form4_1767739662.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,240,909 F1 · kind: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:27 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,961 | $0.00 | $0.00 |
DisclosureSEC source: 0001837016-25-000005 · wk-form4_1759523254.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,238,528 F1 · kind: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 19:30 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,949 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000116 · wk-form4_1751571020.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,236,567 F1 · kind: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 21:22 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 44,031 | $0.00 Strike: $5.11 | $0.00 |
DisclosureSEC source: 0001601830-25-000107 · wk-form4_1750713764.xml · derivative · entry 5 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,031 Underlying: Class A Common Stock · 44,031 shares Expires 2035-06-18 F3 · derivative.exercise_date: The shares subject to this option will vest and become exercisable on the earlier of June 18, 2026 or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 21:22 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 22,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000107 · wk-form4_1750713764.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,234,618 F1 · kind: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 18, 2026 or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 1,132,815 shares of Class A common stock transferred from the Dean Y. Li GRAT on June 10, 2025. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 64,481 | $0.00 Strike: $84.71 | $0.00 |
DisclosureSEC source: 0001127602-25-013039 · form4.xml · derivative · entry 3 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,481 Underlying: Common Stock · 64,481 shares Expires 2035-04-28 F4 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 14,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013039 · form4.xml · derivative · entry 2 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,166 Underlying: Common Stock · 14,166 shares Expires 2028-04-29 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:37 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 2,268 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000056 · wk-form4_1743712643.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,618 F1 · kind: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 23:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 32,621 | $97.94 | $3,194,900.74 |
DisclosureSEC source: 0001127602-25-002346 · form4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,592.15 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/22. Performance shares were paid out at 169 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2024. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:02 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,647 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000005 · wk-form4_1736204554.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,350 F1 · kind: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| October 01, 2024 Filed Oct 4, 2024 22:29 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000171 · wk-form4_1728080993.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,703 F1 · kind: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:40 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,592 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000099 · wk-form4_1720039199.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,778 F1 · kind: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 22:11 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 26,193 | $0.00 Strike: $8.59 | $0.00 |
DisclosureSEC source: 0001601830-24-000069 · wk-form4_1717625475.xml · derivative · entry 5 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,193 Underlying: Class A Common Stock · 26,193 shares Expires 2034-06-03 F2 · derivative.exercise_date: The shares subject to this option will vest and become exercisable on the earlier of June 3, 2025 or the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 22:11 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 13,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000069 · wk-form4_1717625475.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,186 F1 · kind: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 3, 2025 or the day prior to the Issuer's 2025 annual meeting of stockholders, subject to Reporting Person's continued service to the Issuer. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:17 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 65,625 | $0.00 Strike: $129.22 | $0.00 |
DisclosureSEC source: 0001127602-24-013958 · form4.xml · derivative · entry 2 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,625 Underlying: Common Stock · 65,625 shares Expires 2034-04-29 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:43 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,267 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000031 · wk-form4_1712180594.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,089 F1 · kind: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 21:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,702 | $0.00 Strike: $62.07 | $0.00 |
DisclosureSEC source: 0001127602-24-004438 · form4.xml · derivative · entry 3 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,702 shares Expires 2027-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 · derivative.exercise_date: The option became exercisable in equal installments on 5/5/2018, 5/5/2019 and 5/5/2020. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 21:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 14,702 | $125.50 | $1,845,083.36 |
DisclosureSEC source: 0001127602-24-004438 · form4.xml · nonDerivative · entry 2 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,242.37 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.4900 to $125.5330, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 21:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 14,702 | $62.07 | $912,553.14 |
DisclosureSEC source: 0001127602-24-004438 · form4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,944.37 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 21:10 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 25,760 | $119.43 | $3,076,516.80 |
DisclosureSEC source: 0001127602-24-002024 · form4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,242.37 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/21. Performance shares were paid out at 161 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2023. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 23:51 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 962 | $14.03 | $13,495.13 |
DisclosureSEC source: 0001209191-24-001486 · doc4.xml · nonDerivative · entry 2 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Dean Y. Li 2021 Family Trust Disclosed balance after: 421,000 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Trust on August 22, 2023. F4 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $14 to $14.08 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. F3 · ownership.nature: The shares are held by the Dean Y. Li 2021 Family Trust, of which the Reporting Person's spouse serves as trustee. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 23:51 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 28,038 | $13.65 | $382,718.70 |
DisclosureSEC source: 0001209191-24-001486 · doc4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Dean Y. Li 2021 Family Trust Disclosed balance after: 421,962 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Trust on August 22, 2023. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $13 to $13.99 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. F3 · ownership.nature: The shares are held by the Dean Y. Li 2021 Family Trust, of which the Reporting Person's spouse serves as trustee. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 23:11 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000001 · wk-form4_1704409872.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,327,618 F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 21:46 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,659 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-052058 · doc4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,326,415 F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. F2 · balance_after: Reflects 687,295 shares transferred to the Reporting Person from the Dean Y. Li 2021 GRAT Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 22:10 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-041655 · doc4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 637,461 F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 21:23 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 25,224 | $0.00 Strike: $8.92 | $0.00 |
DisclosureSEC source: 0001209191-23-038844 · doc4.xml · derivative · entry 5 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,224 Underlying: Class A Common Stock · 25,224 shares Expires 2033-06-16 F2 · shares: The shares subject to this option will vest and become exercisable on the earlier of June 16, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 21:23 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 12,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038844 · doc4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 636,021 F1 · shares: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 16, 2024 or the day prior to the Issuer's 2024 annual meeting of stockholders, subject to Reporting Person's continued service to the Issuer. Read SEC document |
| May 02, 2023 Filed May 4, 2023 21:56 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 77,455 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0001127602-23-014553 · form4.xml · derivative · entry 2 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,455 Underlying: Common Stock · 77,455 shares Expires 2033-05-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:10 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 1,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014248 · form4.xml · derivative · entry 3 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,062 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:10 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 524 | $115.47 | $60,506.28 |
DisclosureSEC source: 0001127602-23-014248 · form4.xml · nonDerivative · entry 2 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,471.432 Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:10 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 1,062 | $115.47 | $122,629.14 |
DisclosureSEC source: 0001127602-23-014248 · form4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,995.432 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2023 Filed Oct 4, 2023 21:46 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GiftClass A Common Stock | 627,705 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-052058 · doc4.xml · nonDerivative · entry 2 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Dean Y. Li 2021 GRAT Disclosed balance after: 0 F2 · balance_after: Reflects 687,295 shares transferred to the Reporting Person from the Dean Y. Li 2021 GRAT Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 22:00 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,724 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023433 · doc4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 623,409 F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 21:59 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 3,275 | $109.88 | $359,857.00 |
DisclosureSEC source: 0001127602-23-002223 · form4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,933.432 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/20. Performance shares were paid out at 110 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2022. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 23:29 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,573 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002070 · doc4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 621,685 F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| October 03, 2022 Filed Oct 6, 2022 01:15 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-052917 · doc4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 620,112 F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.